Gemini Therapeutics is based in Cambridge, MA. It has raised $216M in total funding. Latest round: IPO.
Gemini Therapeutics funding overview
Gemini Therapeutics is based in Cambridge, MA. Gemini Therapeutics has raised $216M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in February 2021. The round record for Gemini Therapeutics runs through 2021; nothing later has been disclosed. Investors on record include Fidelity Management & Research Company LLC, Wellington Management, Boxer Capital of Tavistock Group, Alyeska Investment Group, L.P., Suvretta Capital Management, CVF and 2 others. 8 distinct backers are named across the disclosed rounds.
Gemini Therapeutics at a glance
Total raised
$216M
Latest round
IPO
Latest round date
February 2021
Headquarters
Cambridge, MA
Notable investors
Fidelity Management & Research Company LLC, Wellington Management, Boxer Capital of Tavistock Group, Alyeska Investment Group, L.P., Suvretta Capital Management, CVF, DAFNA Capital, Acorn Bioventures
Frequently asked about Gemini Therapeutics funding
How much has Gemini Therapeutics raised?
Gemini Therapeutics has raised $216M in total disclosed funding across the rounds on record.
Who has invested in Gemini Therapeutics?
Fidelity Management & Research Company LLC, Wellington Management, Boxer Capital of Tavistock Group, Alyeska Investment Group, L.P., Suvretta Capital Management, CVF are named among the investors backing Gemini Therapeutics.
What was the latest Gemini Therapeutics funding round?
The most recent disclosed round is an IPO, announced in February 2021.
Where is Gemini Therapeutics based?
Gemini Therapeutics is based in Cambridge, MA.
When did Gemini Therapeutics last raise?
The last disclosed Gemini Therapeutics round closed in February 2021 at IPO.
Totals shown for Gemini Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Cambridge and the investors behind them below.
